Galecto Biotech AB

https://www.galecto.com

Galecto Biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company's products target galectins or galactoside binding lectins, which are a group of proteins shown to be involved in many disease processes. Galecto Biotech's high potency galectin inhibitors may open new treatment possibilities for many patients. The company is led by top-level scientists and biotech executives. Galecto Biotech is located in Lund, Sweden, with close proximity to the founders' research groups. *

	Start	2011-01-01 established
	Group	Galecto (Group)
	Industry	pharmaceutical
	Person	Schambye, Hans T. (Galecto Biotech 201111– CEO before OncoNOx + Reception + Gastrotech + Maxygen + ProFound Pharma)
	Person 2	Pedersen, Anders (Galecto Biotech 201304– COO before CMC Biologics + Novo Nordisk + ProFound Pharma)

	Region	København (Copenhagen)
	Country	Denmark
	Street	3 Ole Maaløes Vej Copenhagen Bio Science Park (COBIS)
	City	2200 København
	Tel	+45-2637-3726
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-02-12